A novel marker and therapeutic target of breast cancer HER2 and trastuzumab / 中国癌症杂志
China Oncology
; (12)2001.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-674994
Responsible library:
WPRO
ABSTRACT
Breast cancer is one of the most common tumors in the world. HER2 and anti HER2 monoclonal antibody (Herceptin) has been a focus of breast cancer study in recent years. It is believed that HER2 and anti HER2 monoclonal antibody (Herceptin) may be a novel independent prognostic marker and therapeutic target for breast cancer. Herceptin, anti HER2 monoclonal antibody, has been proved to be an effective agent for breast cancer in late stage diseases, recurrent and metastatic lesion.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
China Oncology
Year:
2001
Document type:
Article